Language

Current Cancer Trials

Participate in One of These Clinical Trials

National Cancer Institute Trials:  

With a grant from the National Cancer Institute (NCI), more than 30 established, recognized clinical oncology programs have joined together to form the Northwest Community Oncology Research Program (NW NCORP).

MultiCare Health System is amongst a network of hospitals, clinics, physicians, and researchers working together to provide cancer education and access to new and unique cancer clinical trials to the men, women, and children in communities across Washington, Utah and Alaska.

Visit NW NCORP website for NCI Clinical Trials available at MultiCare


Other Cancer Clinical Trials offered by MultiCare Health System

Phase I

100036-002

An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors

Protocol Summary

INCB 57643-101

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Protocol Summary


Breast

8093

Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Protocol Summary

CBYL719C2301 (SOLAR-1)

A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Protocol Summary


Pancreas

-None at this time-


Gynecologic

D8488C00001

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Protocol Summary


Leukemia

PCYC-1134 M

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Protocol Summary


Lung

Revolution Registry

For the Evolution of Lung Cancer Therapy and Outcomes Now

No protocol summary available.  Contact Danielle Wahinekapu for more information: 253-697-1201

DSP-DE-MS 14-009

A Study to Determine the Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma From Patients With Non Small Cell Lung Carcinoma (NSCLC)

Protocol Summary

GO29527

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

Protocol Summary

SCCA 7755

A Phase II study of weekly Abraxane (nab-paclitaxel) for patients with advanced NSCLC with EGFR mutations following front-line therapy with EGFR tyrosine kinase inhibitors

Protocol Summary

PM1183-C-003-14

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

Protocol Summary


Melanoma

103A-301

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

Protocol Summary


Other

Precision Med 6504

Collection of Blood, Urine and Tissue Samples from Patients with Solid Malignant Tumors

No protocol summary available.  Contact Holly Covert for more information:  253-403-1278

For more information contact Michelle Maxin-Wells at 253-403-7193 or [email protected]